By Editor • August 31, 2026 • 1 min read
Recent clinical success in melanoma treatments offers renewed hope for mRNA technology, though public skepticism remains a challenge.
Read moreBy Editor • August 24, 2026 • 1 min read
Moderna and Merck's cancer vaccine shows early promise in reducing melanoma recurrence, but skepticism remains among experts and investors.
Read moreBy Editor • August 19, 2026 • 1 min read
Merck and Moderna's personalized mRNA therapy intismeran autogene achieves a milestone in melanoma treatment with positive phase 3 trial results.
Read moreBy Editor • August 19, 2026 • 1 min read
Moderna and Merck's mRNA cancer vaccine shows promise in a Phase 3 trial for melanoma, highlighting advancements in personalized cancer treatment.
Read moreBy Editor • August 19, 2026 • 1 min read
A new mRNA drug has shown promising results in preventing melanoma recurrence, marking a milestone in cancer treatment.
Read moreBy Editor • August 19, 2026 • 1 min read
Merck and Moderna report promising trial results for their melanoma vaccine, intismeran autogene, in combination with Keytruda.
Read moreBy Editor • August 19, 2026 • 1 min read
Heidi Overton is set to be nominated as FDA commissioner, while a new mRNA cancer vaccine shows promise in treating melanoma.
Read more
